Laureate to Manufacture ImmunoGen's huC242 Antibody
PRINCETON, N.J., Nov. 1 /PRNewswire/ -- Laureate Pharma, Inc., a
full-service biopharmaceutical development and protein production company,
is pleased to announce that it has entered into a contract manufacturing
agreement with ImmunoGen, Inc. Laureate Pharma will manufacture for
ImmunoGen the huC242 antibody used in the production of their huC242-DM4
Tumor-Activated Prodrug (TAP) compound, now in Phase II clinical testing.
Terms of the manufacturing agreement were not disclosed.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020723/LPHARMLOGO )
"ImmunoGen is well known for its proprietary TAP technology, which uses
tumor-targeting antibodies to deliver a potent cell-killing agent
specifically to cancer cells," notes Robert J. Broeze, Ph.D., President and
Chief Executive Officer of Laureate Pharma. "Laureate Pharma has an
established track record in the manufacture of protein based
biopharmaceuticals. We are pleased that ImmunoGen chose us to manufacture
their antibody and we are excited to be working with them."
About Laureate Pharma, Inc.
Laureate Pharma is a full-service biopharmaceutical development and
protein production company located in Princeton, New Jersey. Laureate
offers superior bioprocessing services that accelerate new products from
development through production. Laureate provides a wide range of
specialized services from process design and development to full-scale cGMP
production, purification, aseptic filling, testing, validation, analytical
services, and regulatory support. Laureate is focused on two active
segments of the biopharmaceutical industry: monoclonal antibodies and
recombinant protein products. Laureate is a fully owned subsidiary of
Safeguard Scientifics, Inc. (NYSE: SFE), which builds value in growth-stage
technology and life sciences businesses and provides growth capital as well
as a range of strategic, operational and management resources to its
partner companies (http://www.safeguard.com). For more information, contact
Michael Cavanaugh, Vice President Sales, Marketing, and Business
Development at (609) 919-3400, email info@laureatepharma.com or visit
http://www.laureatepharma.com.
SOURCE Laureate Pharma, Inc.
back to top
Related links: http://www.laureatepharma.com/
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20020723/LPHARMLOGO AP Archive: http://photoarchive.ap.org PRN Photo Desk, photodesk@prnewswire.com
CONTACT: Michael Cavanaugh, Vice President Sales, Marketing, and Business Development of Laureate Pharma, Inc., +1-609-919-3400, info@laureatepharma.com
|